01 1Viatris
01 1LAMIVUDINE USP (PROCESS-II)
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2018-11-30
Pay. Date : 2018-07-31
DMF Number : 29613
Submission : 2015-09-01
Status : Active
Type : II
20
Matrix Pharmacorp Private Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is LAMIVUDINE USP (PROCESS-II), with a corresponding US DMF Number 29613.
Remarkably, this DMF maintains an Active status since its submission on September 01, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of November 30, 2018, and payment made on July 31, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II
